quantisnow
FeedTopReportsPricing
⌘K
Live feed
15:45:51·28d
SECFiling
Artivion Inc. logo

Amendment: SEC Form SCHEDULE 13G/A filed by Artivion Inc.

AORT· Artivion Inc.
Health Care
Original source

Companies

  • AORT
    Artivion Inc.
    Health Care

Recent analyst ratings

  • Apr 10UpdateLadenburg Thalmann$42.00
  • Aug 13UpdateLadenburg Thalmann$38.79
  • Jun 17UpdateCanaccord Genuity$35.00
  • Oct 23UpdateJMP Securities$33.00
  • Sep 27UpdateLake Street$28.00
  • Aug 8UpdateLake Street$32.00

Related

  • PR15h
    Artivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial Results
  • ANALYST13d
    Artivion upgraded by Ladenburg Thalmann with a new price target
  • PR17d
    Artivion Announces U.S. FDA Approval of the NEXUS® Aortic Arch System
  • SEC22d
    SEC Form DEFA14A filed by Artivion Inc.
  • SEC22d
    SEC Form DEF 14A filed by Artivion Inc.
  • INSIDER50d
    VP, Chief Accounting Officer Horton Amy sold $34,036 worth of shares (901 units at $37.78) and was granted 7,475 shares, increasing direct ownership by 5% to 139,088 units (SEC Form 4)
  • INSIDER50d
    SVP, General Counsel Holloway Jean F was granted 27,795 shares and sold $485,728 worth of shares (12,805 units at $37.93), increasing direct ownership by 9% to 185,095 units (SEC Form 4)
  • INSIDER50d
    SVP, Clinical & MD Affair Stanton Marshall S. was granted 21,838 shares and sold $81,180 worth of shares (2,149 units at $37.78), increasing direct ownership by 49% to 60,097 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022